Blood Diseases Program

Call for Proposals: 2017 HSCI Blood Program Pilot Grants

July 20, 2017

The Harvard Stem Cell Institute (HSCI) Blood Program invites applications for its 2017 Pilot Grant cycle. The purpose of this funding program is to provide resources for projects in the field of blood stem cell biology with a basic, translational, or clinical research focus. HSCI is seeking to fund groundbreaking, innovative, high-impact research projects that could fundamentally enhance biomedical research in the field. Of particular interest to HSCI at this time

Read more about Call for Proposals: 2017 HSCI Blood Program Pilot Grants

HSCI research inspires startup

November 16, 2016

Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders

Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases

Read more about HSCI research inspires startup